Literature DB >> 28284107

Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study.

Markus Dold1, Lucie Bartova1, Daniel Souery2, Julien Mendlewicz3, Alessandro Serretti4, Stefano Porcelli4, Joseph Zohar5, Stuart Montgomery6, Siegfried Kasper7.   

Abstract

This naturalistic European multicenter study aimed to elucidate the association between major depressive disorder (MDD) and comorbid anxiety disorders. Demographic and clinical information of 1346 MDD patients were compared between those with and without concurrent anxiety disorders. The association between explanatory variables and the presence of comorbid anxiety disorders was examined using binary logistic regression analyses. 286 (21.2%) of the participants exhibited comorbid anxiety disorders, 10.8% generalized anxiety disorder (GAD), 8.3% panic disorder, 8.1% agoraphobia, and 3.3% social phobia. MDD patients with comorbid anxiety disorders were characterized by younger age (social phobia), outpatient status (agoraphobia), suicide risk (any anxiety disorder, panic disorder, agoraphobia, social phobia), higher depressive symptom severity (GAD), polypsychopharmacy (panic disorder, agoraphobia), and a higher proportion receiving augmentation treatment with benzodiazepines (any anxiety disorder, GAD, panic disorder, agoraphobia, social phobia) and pregabalin (any anxiety disorder, GAD, panic disorder). The results in terms of treatment response were conflicting (better response for panic disorder and poorer for GAD). The logistic regression analyses revealed younger age (any anxiety disorder, social phobia), outpatient status (agoraphobia), suicide risk (agoraphobia), severe depressive symptoms (any anxiety disorder, GAD, social phobia), poorer treatment response (GAD), and increased administration of benzodiazepines (any anxiety disorder, agoraphobia, social phobia) and pregabalin (any anxiety disorder, GAD, panic disorder) to be associated with comorbid anxiety disorders. Our findings suggest that the various anxiety disorders subtypes display divergent clinical characteristics and are associated with different variables. Especially comorbid GAD appears to be characterized by high symptom severity and poor treatment response.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anxiety disorders; Comorbidities; Depression; Generalized anxiety disorder; Risk factors; Treatment response

Mesh:

Substances:

Year:  2017        PMID: 28284107     DOI: 10.1016/j.jpsychires.2017.02.020

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  14 in total

1.  Comorbid anxiety in late-life depression: Relationship with remission and suicidal ideation on venlafaxine treatment.

Authors:  Yasmina M Saade; Ginger Nicol; Eric J Lenze; J Philip Miller; Michael Yingling; Julie Loebach Wetherell; Charles F Reynolds; Benoit H Mulsant
Journal:  Depress Anxiety       Date:  2019-11-04       Impact factor: 6.505

2.  Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited.

Authors:  Lucie Bartova; Markus Dold; Hans-Peter Volz; Erich Seifritz; Hans-Jürgen Möller; Siegfried Kasper
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-03-09       Impact factor: 5.270

3.  Predictors of Treatment Resistance Across Different Clinical Subtypes of Depression: Comparison of Unipolar vs. Bipolar Cases.

Authors:  Michele Fornaro; Andrea Fusco; Stefano Novello; Pierluigi Mosca; Annalisa Anastasia; Antonella De Blasio; Felice Iasevoli; Andrea de Bartolomeis
Journal:  Front Psychiatry       Date:  2020-05-15       Impact factor: 4.157

4.  Face Perception in Social Anxiety: Visuocortical Dynamics Reveal Propensities for Hypervigilance or Avoidance.

Authors:  Lisa M McTeague; Marie-Claude Laplante; Hailey W Bulls; Joshua R Shumen; Peter J Lang; Andreas Keil
Journal:  Biol Psychiatry       Date:  2017-10-13       Impact factor: 13.382

Review 5.  Prognosis and improved outcomes in major depression: a review.

Authors:  Christoph Kraus; Bashkim Kadriu; Rupert Lanzenberger; Carlos A Zarate; Siegfried Kasper
Journal:  Transl Psychiatry       Date:  2019-04-03       Impact factor: 6.222

6.  Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study.

Authors:  Gregory W Mattingly; Hongye Ren; Michael Cronquist Christensen; Martin A Katzman; Mircea Polosan; Kenneth Simonsen; Lene Hammer-Helmich
Journal:  Front Psychiatry       Date:  2022-03-09       Impact factor: 4.157

7.  Effects of growth hormone-releasing hormone receptor antagonist MIA-602 in mice with emotional disorders: a potential treatment for PTSD.

Authors:  Lucia Recinella; Annalisa Chiavaroli; Giustino Orlando; Claudio Ferrante; Serena Veschi; Alessandro Cama; Guya Diletta Marconi; Francesca Diomede; Iacopo Gesmundo; Riccarda Granata; Renzhi Cai; Wei Sha; Andrew V Schally; Luigi Brunetti; Sheila Leone
Journal:  Mol Psychiatry       Date:  2021-07-30       Impact factor: 15.992

8.  The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study.

Authors:  Changsu Han; Sheng-Min Wang; Won-Myong Bahk; Soo-Jung Lee; Ashwin A Patkar; Prakash S Masand; Chi-Un Pae
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-11-20       Impact factor: 2.582

9.  Impact on Mental Health Due to COVID-19 Pandemic: Cross-Sectional Study in Portugal and Brazil.

Authors:  Lígia Passos; Filipe Prazeres; Andreia Teixeira; Carlos Martins
Journal:  Int J Environ Res Public Health       Date:  2020-09-17       Impact factor: 3.390

10.  Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study.

Authors:  George I Papakostas; Maurizio Fava; Marlene P Freeman; Richard C Shelton; Michael E Thase; Manish K Jha; Madhukar H Trivedi; Bryan Dirks; Keith Liu; Srdjan Stankovic
Journal:  Int Clin Psychopharmacol       Date:  2020-11       Impact factor: 2.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.